EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Reverse activity-based protein profiling identifies a class of METTL16 covalent inhibitors

Jingjing Zhang, Fengting Liu, Qian Zhang, Xiaomeng Chai, Jingnan Huang, Xiaofeng Zhuo, Huan Tang, Jingjing Liao, Lingyun Dai, Zhijie Li, Piao Luo, Chuanbin Yang und 2 weitere

Cancer Bioscience · 2026

DOI: 10.1016/j.cbs.2026.100001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Bioscience, 2026. Verfasst von Jingjing Zhang und 13 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Academy of Chinese Medical Sciences, Shenzhen Science and Technology Innovation Program.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Covalent inhibition of disease-associated proteins offers a rapid and robust strategy for drug discovery. METTL16, an RNA N6-methyladenosine (m6A) methyltransferase, plays oncogenic roles in multiple cancers, yet its effective covalent inhibitors remain limited.

Methods

We employed a reverse activity-based protein profiling (reverse ABPP) using a library of natural products and clinically approved drugs to identify covalent binders of METTL16. Recombinant METTL16 and its MTase domain were used for in vitro labeling, competitive binding, and enzymatic inhibition assays. Binding sites were mapped via LC-MS/MS, and molecular dynamics simulations assessed the impact of covalent modification on RNA binding and methylation activity. We also evaluated changes in the METTL16 interactome upon treatment with gallic acid (GA). GA derivatives were analyzed to probe structure–activity relationships.

Results

GA was identified as a covalent inhibitor of METTL16, forming bonds with residues K252 and C253 within the RNA-binding groove. Molecular dynamics simulations indicated that such binding impairs substrate positioning and methylation activity. GA also disrupted METTL16’s interactions with translation machinery in cells. Structure–activity analysis revealed that the pyrogallol moiety is essential for covalent targeting, whereas carboxyl modifications had a limited impact. Indeed, epigallocatechin-3-gallate (EGCG), containing two pyrogallol groups, exhibited stronger inhibition and enhanced suppression of cancer cell proliferation compared to GA.

Conclusions

Reverse ABPP enabled rapid identification of METTL16 covalent inhibitors, highlighting pyrogallol as an effective reactive warhead. GA and EGCG serve as promising lead compounds. This strategy provides a framework for the development of targeted covalent inhibitors against METTL16 and other therapeutically important protein targets.

Förderung

  • China Academy of Chinese Medical Sciences
  • Shenzhen Science and Technology Innovation Program

Zitieren

APA

Zhang, J., Liu, F., Zhang, Q., Chai, X., Huang, J., Zhuo, X., Tang, H., Liao, J., Dai, L., Li, Z., Luo, P., Yang, C., Wang, J., & Xu, C. (2026). Reverse activity-based protein profiling identifies a class of METTL16 covalent inhibitors. Cancer Bioscience. https://doi.org/10.1016/j.cbs.2026.100001

Vancouver

Zhang J, Liu F, Zhang Q, Chai X, Huang J, Zhuo X, et al. Reverse activity-based protein profiling identifies a class of METTL16 covalent inhibitors. Cancer Bioscience. 2026. doi:10.1016/j.cbs.2026.100001

BibTeX
@article{Zhang2026,
  author = {Zhang, Jingjing and Liu, Fengting and Zhang, Qian and Chai, Xiaomeng and Huang, Jingnan and Zhuo, Xiaofeng and Tang, Huan and Liao, Jingjing and Dai, Lingyun and Li, Zhijie and Luo, Piao and Yang, Chuanbin and Wang, Jigang and Xu, Chengchao},
  title = {Reverse activity-based protein profiling identifies a class of METTL16 covalent inhibitors},
  journal = {Cancer Bioscience},
  year = {2026},
  doi = {10.1016/j.cbs.2026.100001}
}
Kostenlos starten →